Product & Industry News
Drug Discovery World
CatalYm to present data on targeting novel checkpoint GDF-15 for immunotherapy of cancer at AACR Annual Meeting

CatalYm to present data on targeting novel checkpoint GDF-15 for immunotherapy of cancer at AACR Annual Meeting

19 June 2020

CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June.

Tumor-derived GDF-15 suppresses T-lymphocyte recruitment to the tumor microenvironment describes in vitro and in vivo data, which demonstrate that tumour cells secrete GDF-15 to block T-cell entry into tumour tissue. Neutralising GDF-15 with CatalYm‘s proprietary antibody (CTL-002) restored the ability of CD8+ T-cells to enter the tumour.

Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cellexclusion in tumors and resistance to anti-PD-1 treatment reveals that melanoma patients with high GDF-15 levels have significantly shorter survival and are less likely to respond to anti-PD1 therapy. In addition, intratumoral GDF-15 levels in human melanoma correlated inversely with CD3+ and CD8+ T cell infiltration. Consequently, GDF-15 may serve as a predictive biomarker for anti-PD1 response and potentially represents a novel target in the immunotherapy of cancer to improve tumour immune cell infiltration and response to cancer immunotherapy.

Dr. Manfred Rüdiger, CEO of CatalYm, said: “Our data shows that GDF-15 is a novel checkpoint factor secreted by tumours. GDF-15 serves as T cell repellent and may cause low or no response to modern immunotherapies. Neutralising GDF-15 with our CTL-002 antibody is a novel promising approach to increase response rates of cancer immunotherapies and overall survival of cancer patients.”

CTL-002 is set to enter clinical development during 2020.

Image credit: Bogomil Mihaylor

More on this subject...
The apocalyptic horsemen of the pharma industry cartoon illustration

The Apocalyptic Horsemen of Drug Discovery and Development READ MORE

A roadmap for achieving self-sustainability of academic high throughput screening core facilities READ MORE

Editing the Human Genome: Role in Functional Genomics and Translational Medicine READ MORE

New Tools Increase Accessibility to High Content Screening Assays READ MORE

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery Main Image

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery READ MORE

In Vivo Imaging In Drug Development: Gamma Scintigraphy READ MORE

Innovate while derisking drug development - yes we can!

Innovate While Derisking Drug Development: Yes We Can! READ MORE

Stem cells, cell-based assays and the world of small molecules

Stem Cells: Cell-Based Assays and the World of Small Molecules READ MORE

Pharmaceutical and biomedical research likely to use 1 billion dollars worth of microfluidics devices by 2016

Pharmaceutical & biomedical research likely to use $1 billion worth of microfluidics devices by 2016 READ MORE

Asian innovation

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry READ MORE